Publications by authors named "Roy Eshet"

Claim this Profile
S
Safety Outcomes with the Long-Acting Subcutaneous Antipsychotic TV-46000 in Schizophrenia: A Post Hoc Analysis of Behavioral, Neuromotor, Endocrine, and Cardiometabolic Outcomes from Two Phase 3 Studies.
Christoph U Correll, Helena Knebel, Eran Harary, Roy Eshet, Orna Tohami

CNS Drugs· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of Long-Term Treatment with TV-46000 on Symptom Improvement Over Time in Stabilized Patients with Schizophrenia.
John M Kane, Orna Tohami, Kelli R Franzenburg, Mark Suett, Nir Sharon, Roy Eshet

CNS Drugs· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
TV-46000, A Long-Acting Subcutaneous Antipsychotic Agent, Demonstrated Improved Patient-Centered Outcomes in Patients with Schizophrenia.
Leslie Citrome, Mark Suett, Kelli R Franzenburg, Roy Eshet, Anna Elgart

Neuropsychiatr Dis Treat· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Long-Term Safety and Tolerability Study of TV-46000 for Subcutaneous Use in Patients with Schizophrenia: A Phase 3, Randomized, Double-Blinded Clinical Trial.
John M Kane, Roy Eshet, Eran Harary, Orna Tohami, Anna Elgart

CNS Drugs· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of TV-46000, a long-acting, subcutaneous, injectable formulation of risperidone, for schizophrenia: a randomised clinical trial in the USA and Bulgaria.
John M Kane, Eran Harary, Roy Eshet, Orna Tohami, Mark Weiser

Lancet Psychiatry· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis